Petros Pharmaceuticals, Inc.
PTPI
$0.032
$0.00082.56%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -53.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -53.98% | |||
| Cost of Revenue | -- | -7.74% | |||
| Gross Profit | -- | -64.28% | |||
| SG&A Expenses | 0.59% | -37.01% | |||
| Depreciation & Amortization | -- | -11.27% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -41.02% | -36.86% | |||
| Operating Income | 16.53% | 25.33% | |||
| Income Before Tax | 87.07% | -317.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 87.07% | -317.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 75.63% | -317.59% | |||
| EBIT | 16.53% | 25.33% | |||
| EBITDA | 31.21% | 31.83% | |||
| EPS Basic | 64.87% | -99.96% | |||
| Normalized Basic EPS | 93.38% | -176.18% | |||
| EPS Diluted | 64.87% | -99.96% | |||
| Normalized Diluted EPS | 93.38% | -176.18% | |||
| Average Basic Shares Outstanding | 187.36% | 2.82% | |||
| Average Diluted Shares Outstanding | 187.36% | 2.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||